Reference entry
Vesilute (ED)
ED Dipeptide · Bladder & Urinary Tract Bioregulator
Overview
Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.
Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.
Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
May support overall urinary tract function and tissue health.
Potential benefits for pelvic tissue health and function.
Research indicates potential to enhance blood flow and reduce dysfunction in prostate tissue.
Mechanism
Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.
Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.
Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
Research areas
- Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.
- Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.
- Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
- May support overall urinary tract function and tissue health.
- Potential benefits for pelvic tissue health and function.
- Research indicates potential to enhance blood flow and reduce dysfunction in prostate tissue.
- May help alleviate symptoms associated with benign prostatic hyperplasia.
- Part of comprehensive bioregulator protocols addressing age-related urogenital changes.
- Supports cellular regeneration in urinary and reproductive tissues.
Research notes
- Generally well-tolerated
- Injection site reactions (mild, if injectable)
- Minimal reported side effects
- Signs of allergic reaction
- Unusual urinary symptoms
- Unexpected changes in urination patterns
- Known hypersensitivity to peptide components
- Active urinary tract infection (treat first)
- Pregnancy or breastfeeding
- Prostate cancer (consult physician)
FAQs
Does Vesilute specifically help with prostate health or only bladder function?
Vesilute targets both bladder smooth muscle function and prostate health through enhanced blood flow and tissue regeneration. Research indicates potential for relieving BPH (benign prostatic hyperplasia) symptoms, though clinical evidence is limited. The dipeptide's small size allows penetration into prostatic tissue for direct cellular effects.
How is Vesilute different from Prostamax or other prostate-targeting peptides?
Vesilute (ED dipeptide) is a specific Khavinson bioregulator focusing on bladder and smooth muscle regulation, while Prostamax targets prostate tissue directly. They're complementary - Vesilute works on urinary tract function; Prostamax on prostate inflammation. Combining them may provide comprehensive urogenital support.
Can Vesilute improve urinary symptoms in women?
While Vesilute is studied primarily in men for prostate support, its bladder smooth muscle regulatory and microcirculation enhancement effects could theoretically benefit women with bladder dysfunction or urinary symptoms. Gender-specific research is limited, but the mechanism suggests potential for both sexes.
How long does Vesilute take to improve urinary flow or BPH symptoms?
Khavinson bioregulators typically require cycling (10-20 days on, then break) with improvements developing over 2-4 weeks during the first cycle. Maximum benefits emerge after multiple cycles (2-3 per year). Effects persist between cycles due to epigenetic changes, but bioregulator action is gradual compared to pharmaceutical diuretics.